.Nature Medicine, Released online: 03 September 2024 doi:10.1038/ s41591-024-03223-zThis Viewpoint asks for introduction of patients along with MASLD as well as size of liver end results in cardio-- renal-- metabolic trials, when information suggest mechanistically plausible benefits and professional safety-- as well as outlines points to consider for test concept as well as regulative approval.